Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE)
Completed
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3
1987-04-01
To compare the efficacy of amiodarone to conventional anti-arrhythmic therapy in individuals
who had survived one episode of out-of-hospital cardiac arrest.
Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE)
Completed
University of Washington
Phase 3
1987-04-01
To compare the efficacy of amiodarone to conventional anti-arrhythmic therapy in individuals
who had survived one episode of out-of-hospital cardiac arrest.
Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)
Completed
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3
1995-03-01
To compare two standard treatment strategies for atrial fibrillation: ventricular rate
control and anticoagulation vs. rhythm control and anticoagulation.
Multicenter Study of Antiarrhythmic Medications for Treatment of Infants With Supraventricular Tachycardia
Completed
The Hospital for Sick Children
Phase 3
2006-10-01
This is a randomized, double-blind, multi-centered study to compare 6 months of medical
treatment with digoxin or propranolol in infants with SVT Background: SVT is the most common
sustained arrhythmia of infancy. Neither digoxin nor propranolol has been evaluated for
pediatric use in a controlled trial in the context of SVT, yet both medications are used
frequently.
Specific aims of the study:
To determine whether propranolol and digoxin differ in the:
1. Incidence of recurrent SVT in infants after 6 months of treatment with propranolol or
digoxin
2. Time to first recurrence of SVT in infants treated with propranolol or digoxin.
3. Incidence of adverse outcomes in infants treated with propranolol or digoxin.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
